Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DFD-07 Cream
DFD-07 · 1 trial · 1 indication
Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)
| Arm | Type | Description |
|---|---|---|
| DFD-07 cream | EXPERIMENTAL | DFD-07 cream applied twice daily |
| Placebo cream | PLACEBO_COMPARATOR | Placebo cream applied twice daily |
| Name | Type | Description |
|---|---|---|
| DFD-07 Cream | DRUG | - |
| Placebo Cream | DRUG | - |
Inclusion Criteria: To be eligible for the study, the patients have to fulfil all of the following criteria at Visit 1: 1. Written informed consent has been signed and dated prior to any study related procedure or initiation of a wash out period 2. Skin type I, II or III according to Fitzpatrick 3...
DFD-07 is an investigational small molecule being studied for the treatment of actinic keratosis, a skin condition affecting the face and scalp. It is being developed as a topical cream by Dr. Reddy's Laboratories Ltd. It is not yet approved for commercial use and remains in clinical development.
DFD-07 is being developed by Dr. Reddy's Laboratories Ltd, which trades on the New York Stock Exchange under the ticker RDY. The company is studying the asset as a topical small molecule therapy in dermatology, specifically for actinic keratosis of the face and scalp.
DFD-07 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA or any other regulatory authority for the treatment of actinic keratosis.
DFD-07 has been evaluated in one completed Phase 2 trial, NCT02654717, titled "Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp." The trial enrolled 111 participants in Germany, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.
Yes, DFD-07 Cream is another name for DFD-07. Both refer to the same investigational topical small molecule developed by Dr. Reddy's Laboratories Ltd for actinic keratosis. Searches using either name point to the same Phase 2 asset and the same completed trial, NCT02654717.